Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

VALEANT PHARMACEUTICALS INTL INC > Some Observations
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by StocknerdEQcoolon May 14, 2016 8:07pm
101 Views
Post# 24874104

RE:RE:RE:RE:Some Observations

RE:RE:RE:RE:Some Observations
Marky, In a scenario where VRX should split into A, B and C .... companies then in theory shareholders would get shares of A, B and C ....companies . But there is a lot of technical difficulties for this kind of restructuring which the financial people have to overcome in order to get stakeholders approval. Therefore, this scenario is not in the horizon now.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities